|
|
|
|
| LEADER |
01000naa a22002652c 4500 |
| 001 |
NLM392131633 |
| 003 |
DE-627 |
| 005 |
20250906235524.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
250906s2025 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202510293
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1559.xml
|
| 035 |
|
|
|a (DE-627)NLM392131633
|
| 035 |
|
|
|a (NLM)40913574
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wu, Qinghe
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nanomedicine Reimagined
|b Translational Strategies for Precision Tumor Theranostics
|
| 264 |
|
1 |
|c 2025
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 06.09.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2025 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Nanomedicine has shown remarkable promise in advancing tumor imaging and therapy through its ability to achieve targeted delivery, precision imaging, and therapeutic efficacy. However, translating these preclinical successes into clinical practice remains fraught with challenges, including inconsistent tumor targeting, off-target organ accumulation, and a lack of comprehensive understanding of in vivo behavior of nanomedicines. In this perspective, the current state of nanomedicine research is critically analyzed, emphasizing the translational bottlenecks and offering a forward-looking view on potential solutions. The enhanced permeability and retention (EPR) effect are revisited, dissecting its variable relevance across small animals, large animals, and human patients. Emerging strategies are also discussed to overcome its limitations, such as active targeting and bioengineered delivery systems. Highlighting the need for multimodal imaging, it is proposed to combine nuclear imaging for deep-tissue penetration with high-resolution optical imaging to refine our understanding of nanomedicine biodistribution and tumor targeting. Additionally, nonspecific uptake in organs like the liver and spleen is examined, advocating for strategies such as carrier surface modification and biomimetic design to enhance tumor specificity. Moving forward, integrate advanced technologies such as artificial intelligence (AI)-driven data analytics and humanized in vitro and in vivo models are proposed to better predict clinical outcomes. By critically synthesizing the current knowledge and proposing transformative directions, this review aims to inspire innovative approaches that will pave the way for nanomedicines to achieve their full clinical potential in tumor theranostics
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a EPR effect
|
| 650 |
|
4 |
|a active targeting
|
| 650 |
|
4 |
|a artificial intelligence
|
| 650 |
|
4 |
|a cancer nanomedicine
|
| 650 |
|
4 |
|a clinical translation
|
| 700 |
1 |
|
|a Yao, Xiaotong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Duan, Xurui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xiaoyuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Jingjing
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2025) vom: 06. Sept., Seite e10293
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g year:2025
|g day:06
|g month:09
|g pages:e10293
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202510293
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2025
|b 06
|c 09
|h e10293
|